tbuckley/cabot-search huggingface dataset:
Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?
Authors: Nicolas Vodovar, Alain Cohen-Solal, Damien Logeart
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
Authors: C. Benedikt Westphalen, Alexander D. Fine, Fabrice André, Shridar Ganesan, Volker Heinemann, Etienne Rouleau, Clare Turnbull, Luis Garcia Palacios, Jorge-Antonio Lopez, Ethan S. Sokol, Joaquin Mateo
Journal: Clinical Cancer Research (2021)

To study associations across tumor types between genome-wide loss of heterozygosity (gLOH) and alterations in homologous recombination repair (HRR)-associated genes beyond BRCA1 and BRCA2.
Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial Infarction
Authors: Yun Wang, Erica C. Leifheit, Harlan M. Krumholz
Journal: JAMA Cardiology (2022)

Short-term outcomes after acute myocardial infarction (AMI) have improved, but little is known about longer-term outcomes.To evaluate trends in 10-year all-cause mortality and hospitalization for recurrent AMI by demographic subgroups and examine the association between recurrence and mortality.Medicare fee-for-service beneficiaries who survived after AMI from 1995 to 2019. Subgroups were defined by age, sex, race, dual Medicare-Medicaid-eligible status, and residence in health priority areas (geographic areas with persistently high adjusted mortality and hospitalization rates). Data were analyzed from October 2020 to February 2022.Medicare fee-for-service beneficiaries who survived an AMI.Ten-year all-cause mortality and hospitalization for recurrent AMI, beginning 30 days from the index AMI admission.Of an included 3 982 266 AMI survivors, 1 952 450 (49.0%) were female, and the mean (SD) age was 78.0 (7.4) years. Ten-year mortality and recurrent AMI rates were 72.7% (95% CI, 72.6-72.7) and 27.1% (95% CI, 27.0-27.2), respectively. Adjusted annual reductions were 1.5% (95% CI, 1.4-1.5) for mortality and 2.7% (95% CI, 2.6-2.7) for recurrence. In subgroup analyses balancing patient characteristics, hazard ratios (HRs) for mortality and recurrence were 1.13 (95% CI, 1.12-1.13) and 1.07 (95% CI, 1.06-1.07), respectively, for men vs women; 1.05 (95% CI, 1.05-1.06) and 1.08 (95% CI, 1.07-1.09) for Black vs White patients; 0.96 (95% CI, 0.95-0.96) and 1.00 (95% CI, 1.00-1.01) for other race (including American Indian and Alaska Native, Asian, Hispanic, other race or ethnicity, and unreported) vs White patients; 1.24 (95% CI, 1.24-1.24) and 1.21 (95% CI, 1.20-1.21) for dual Medicare-Medicaid-eligible vs non-dual Medicare-Medicaid-eligible patients; and 1.06 (95% CI, 1.06-1.07) and 1.00 (95% CI, 1.00-1.01) for patients in health priority areas vs other areas. For patients hospitalized in 2007 to 2009, the last 3 years for which full 10-year follow-up data were available, 10-year mortality risk was 13.9% lower than for those hospitalized in 1995 to 1997 (adjusted HR, 0.86; 95% CI, 0.85-0.87) and 10-year recurrence risk was 22.5% lower (adjusted HR, 0.77; 95% CI, 0.76-0.78). Mortality within 10 years after the initial AMI was higher for patients with a recurrent AMI (80.6%; 95% CI, 80.5-80.7) vs those without recurrence (72.4%; 95% CI, 72.3-72.5).In this study, 10-year mortality and hospitalization for recurrence rates improved over the last decades for patients who survived the acute period of AMI. There were marked differences in outcomes and temporal trends across demographic subgroups, emphasizing the urgent need for prioritization of efforts to reduce inequities in long-term outcomes.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia
Authors: Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Journal: Clinical Cancer Research (2021)

Abstract Purpose: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53–MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Patients and Methods: Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12.5–350 mg) and 2A (days 1–14; 28-day cycle; dose 1–20 mg). Alternative regimens included 1B (days 1 and 8; 28-day cycle) and 2C (days 1–7; 28-day cycle). The primary endpoint was incidence of dose-limiting toxicities (DLT) during cycle 1. Results: Overall, 115 patients with solid tumors and 93 with hematologic malignancies received treatment. DLTs occurred in 8/92 patients with solid tumors and 10/53 patients with hematologic malignancies. In solid tumors, an RDE of 120 mg was defined in 1B. In hematologic tumors, RDEs were defined in 1A: 250 mg, 1B: 120 mg, and 2C: 45 mg. More patients with hematologic malignancies compared with solid tumors experienced grade 3/4 treatment-related adverse events (71% vs. 45%), most commonly resulting from myelosuppression. These were more frequent and severe in patients with hematologic malignancies; 22 patients exhibited tumor lysis syndrome. Overall response rates at the RDEs were 10.3% [95% confidence interval (CI), 2.2–27.4] in solid tumors and 4.2% (95% CI, 0.1–21.1), 20% (95% CI, 4.3–48.1), and 22.2% (95% CI, 8.6–42.3) in acute myeloid leukemia (AML) in 1B, 1A, and 2C, respectively. Conclusions: A common safety profile was identified and preliminary activity was noted, particularly in AML. Comprehensive investigation of dosing regimens yielded recommended doses/regimens for future combination studies.
In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose
Authors: Bruno P. Granwehr
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubMay 2022In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second doseBruno P. Granwehr, MD, MSBruno P. Granwehr, MD, MSUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.P.G.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationDunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531-43. https://pubmed.ncbi.nlm.nih.gov/34910859Clinical Impact RatingsGIM/FP/GP: References1. Richard SA, Epsi NJ, Pollett S, et al. Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) instrument in patients with coronavirus disease 2019. Open Forum Infect Dis. 2021;8:ofab517. [PMID: 34901299] Google Scholar2. Spear ML, Diaz-Papkovich A, Ziv E, et al. Recent shifts in the genomic ancestry of Mexican Americans may alter the genetic architecture of biomedical traits. Elife. 2020;9:e56029. [PMID: 33372659] Google Scholar3. Jethwa H, Wong R, Abraham S. COVID-19 vaccine trials: ethnic diversity and immunogenicity. Vaccine 2021;39:3541-3. [PMID: 34049734] Google Scholar Author, Article, and Disclosure InformationAuthors: Bruno P. Granwehr, MD, MSAffiliations: University of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.P.G.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0028.This article was published at Annals.org on 3 May 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPlants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and VaccinationIntranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2 May 2022Volume 175, Issue 5Page: JC52KeywordsCOVID-19Clinical trialsPolymerase chain reactionResearch laboratoriesReverse transcriptase polymerase chain reactionReverse transcriptionSafetyTemperatureVaccines ePublished: 3 May 2022 Issue Published: May 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Impact of Exposure to Diesel Exhaust on Inflammation Markers and Proteases in Former Smokers with Chronic Obstructive Pulmonary Disease: A Randomized, Double-blinded, Crossover Study
Authors: Min Hyung Ryu, Tina Afshar, Hang Li, Denise J. Wooding, Juma Orach, Jin Sheng Zhou, Shane Murphy, Kevin S. K. Lau, Carley Schwartz, Agnes C. Y. Yuen, Christopher F. Rider, Chris Carlsten
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: There is growing evidence that chronic obstructive pulmonary disease (COPD) can be caused and exacerbated by air pollution exposure. Objectives: To document the impact of short-term air pollution exposure on inflammation markers, proteases, and antiproteases in the lower airways of older adults with and without COPD. Methods: Thirty participants (10 ex-smokers with mild to moderate COPD and 20 healthy participants [9 ex-smokers and 11 never-smokers]), with an average age of 60 years, completed this double-blinded, controlled, human crossover exposure study. Each participant was exposed to filtered air (control) and diesel exhaust (DE), in washout-separated 2-hour periods, in a randomly assigned order. Bronchoscopy was performed 24 hours after exposure to collect lavage. Cell counts were performed on blood and airway samples. ELISAs were performed to measure acute inflammatory proteins, matrix proteinases, and antiproteases in the airway and blood samples. Measurements and Main Results: In former smokers with COPD, but not in the other participants, exposure to DE increased serum amyloid A (effect estimate, 1.67; 95% confidence interval [CI], 1.21–2.30; P = 0.04) and matrix metalloproteinase 10 (effect estimate, 2.61; 95% CI, 1.38–4.91; P = 0.04) in BAL. Circulating lymphocytes were increased after DE exposure (0.14 [95% CI, 0.05–0.24] cells × 109/L; P = 0.03), irrespective of COPD status. Conclusions: A controlled human crossover study of DE exposure reveals that former smokers with COPD may be susceptible to an inflammatory response compared with ex-smokers without COPD or never-smoking healthy control participants. Clinical trial registered with www.clinicaltrials.gov (NCT 02236039).
<i>BCOR</i> and <i>BCORL1</i> Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes
Authors: Eva J. Schaefer, Helen C. Wang, Hannah Q. Karp, Clifford A. Meyer, Paloma Cejas, Micah D. Gearhart, Emmalee R. Adelman, Iman Fares, Annie Apffel, Klothilda Lim, Yingtian Xie, Christopher J. Gibson, Monica Schenone, H. Moses Murdock, Eunice S. Wang, Lukasz P. Gondek, Martin P. Carroll, Rahul S. Vedula, Eric S. Winer, Jacqueline S. Garcia, Richard M. Stone, Marlise R. Luskin, Steven A. Carr, Henry W. Long, Vivian J. Bardwell, Maria E. Figueroa, R. Coleman Lindsley
Journal: Blood Cancer Discovery (2021)

Polycomb repressive epigenetic complexes are recurrently dysregulated in cancer. Unlike polycomb repressive complex 2 (PRC2), the role of PRC1 in oncogenesis and therapy resistance is not well-defined. Here, we demonstrate that highly recurrent mutations of the PRC1 subunits BCOR and BCORL1 in leukemia disrupt assembly of a noncanonical PRC1.1 complex, thereby selectively unlinking the RING-PCGF enzymatic core from the chromatin-targeting auxiliary subcomplex. As a result, BCOR-mutated PRC1.1 is localized to chromatin but lacks repressive activity, leading to epigenetic reprogramming and transcriptional activation at target loci. We define a set of functional targets that drive aberrant oncogenic signaling programs in PRC1.1-mutated cells and primary patient samples. Activation of these PRC1.1 targets in BCOR-mutated cells confers acquired resistance to treatment while sensitizing to targeted kinase inhibition. Our study thus reveals a novel epigenetic mechanism that explains PRC1.1 tumor-suppressive activity and identifies a therapeutic strategy in PRC1.1-mutated cancer.We demonstrate that BCOR and BCORL1 mutations in leukemia unlink PRC1.1 repressive function from target genes, resulting in epigenetic reprogramming and activation of aberrant cell signaling programs that mediate treatment resistance. Our study provides mechanistic insights into the pathogenesis of PRC1.1-mutated leukemia that inform novel therapeutic approaches. This article is highlighted in the In This Issue feature, p. 85.
Trends in Transcatheter vs Surgical Mitral Valve Repair Among Medicare Beneficiaries, 2012 to 2019
Authors: Michael N. Young, Stephen Kearing, Mazen A. Albaghdadi, Azeem Latib, Alexander Iribarne
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma
Authors: Meghan C. Ferrall-Fairbanks, Nicholas H. Chakiryan, Boris I. Chobrutskiy, Youngchul Kim, Jamie K. Teer, Anders Berglund, James J. Mulé, Michelle Fournier, Erin M. Siegel, Jasreman Dhillon, Seyed Shayan A. Falasiri, Juan F. Arturo, Esther N. Katende, George Blanck, Brandon J. Manley, Philipp M. Altrock
Journal: Cancer Research (2022)

Abstract Immune-modulating systemic therapies are often used to treat advanced cancer such as metastatic clear cell renal cell carcinoma (ccRCC). Used alone, sequence-based biomarkers neither accurately capture patient dynamics nor the tumor immune microenvironment. To better understand the tumor ecology of this immune microenvironment, we quantified tumor infiltration across three distinct ccRCC patient tumor cohorts using complementarity determining region-3 (CDR3) sequence recovery counts in tumor-infiltrating lymphocytes and a generalized diversity index (GDI) for CDR3 sequence distributions. GDI can be understood as a curve over a continuum of diversity scales that allows sensitive characterization of distributions to capture sample richness, evenness, and subsampling uncertainty, along with other important metrics that characterize tumor heterogeneity. For example, richness quantified the total unique sequence count, while evenness quantified similarities across sequence frequencies. Significant differences in receptor sequence diversity across gender and race revealed that patients with larger and more clinically aggressive tumors had increased richness of recovered tumoral CDR3 sequences, specifically in those from T-cell receptor alpha and B-cell immunoglobulin lambda light chain. The GDI inflection point (IP) allowed for a novel and robust measure of distribution evenness. High IP values were associated with improved overall survival, suggesting that normal-like sequence distributions lead to better outcomes. These results propose a new quantitative tool that can be used to better characterize patient-specific differences related to immune cell infiltration, and to identify unique characteristics of tumor-infiltrating lymphocyte heterogeneity in ccRCC and other malignancies. Significance: Assessment of tumor-infiltrating T-cell and B-cell diversity in renal cell carcinoma advances the understanding of tumor-immune system interactions, linking tumor immune ecology with tumor burden, aggressiveness, and patient survival. See related commentary by Krishna and Hakimi, p. 764
Ivosidenib Boosts OS in Cholangiocarcinoma
Journal: Cancer Discovery (2021)

Ivosidenib extends overall survival in patients with previously treated, advanced cholangiocarcinoma whose disease harbors IDH1 mutations. Median overall survival was 10.3 months in patients who received the drug, versus 7.5 months in the placebo group. The difference was even larger-5.1 months-when researchers accounted for patient crossover into the treatment group.
Health Care Reform under the Biden Administration — Broad Ambitions, Narrow Majorities
Authors: Jonathan Oberlander
Journal: New England Journal of Medicine (2022)

Interview with Dr. Jonathan Oberlander on health care successes and struggles under the Biden administration. (08:37)Download The Biden administration has made important incremental progress in expanding access to affordable health insurance. But its struggles to enact a broader reform agenda reflect the daunting political constraints that limit U.S. health policy.
Abstract P234: Electronic Medical Record Use Among Adults With Self-reported Hypertension: Analysis Of The 2020 Health Information National Trends Survey
Authors: Erin Spaulding, Hailey Miller, Ruth-Alma Turkson-Ocran, Binu Koirala, Oluwabunmi Ogungbe, Samuel Byiringiro, Uchenna Nwokeji, Kelly T Gleason, Diana Baptiste, Seth S Martin, Yvonne Commodore-Mensah
Journal: Circulation (2022)

Background: Nearly half of adults in the United States have hypertension (HTN). Given the rapid uptake of electronic medical records (EMRs), providing patients with access to their EMR has emerged as a viable tool to improve adherence to guideline-directed medical therapy and blood pressure control. However, little is known about the prevalence of and sociodemographic differences in EMR use among adults with HTN. Methods: We used cross-sectional data from the 2020 Health Information National Trends Survey (HINTS) among English and Spanish speaking adults to examine (1) the prevalence of EMR use between individuals with and without self-reported HTN, and (2) social determinants of EMR use among individuals with self-reported HTN. EMR use was dichotomized into not having used and having used an EMR at least once in the past 12 months. Self-reported HTN was defined as having been told by a doctor or health professional that they had HTN. Weighted analyses were conducted by fitting generalized linear models using multivariable Poisson regression to determine independent sociodemographic determinants of EMR use among adults with HTN. Results: Among 3,805 respondents, 36% reported having HTN. About 44% of respondents with versus 38% without HTN reported accessing their EMR at least once in the past 12 months ( P =0.04). Among adults with HTN, the mean age was 56 (SE: 0.67) years, 52% were men, and 67% were Non-Hispanic White. Among adults with HTN, those with lower education [≤ high school graduate: aPR: 0.70 (95% CI: 0.53 - 0.93)], lower income [≤$34,999: aPR: 0.70 (95% CI: 0.50 - 0.97)], and not using the internet [aPR: 0.21 (95% CI: 0.11 - 0.38)] were less likely to report EMR use (Table). Conclusion: EMR use was higher among individuals with HTN, indicating that EMRs may be a useful tool for HTN management. Social determinants such as lower education and income were associated with no EMR use. Policies aimed at improving internet access are needed to ensure equitable access to EMRs for individuals with HTN.
Mutated <i>SETBP1</i> activates transcription of Myc programs to accelerate <i>CSF3R</i>-driven myeloproliferative neoplasms
Authors: Sarah A. Carratt, Garth L. Kong, Brittany M. Curtiss, Zachary Schonrock, Lauren Maloney, Breanna N. Maniaci, Hunter Z. Blaylock, Adrian Baris, Brian J. Druker, Theodore P. Braun, Julia E. Maxson
Journal: Blood (2022)
Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer
Authors: Mingjie An, Hanhao Zheng, Jian Huang, Yan Lin, Yuming Luo, Yao Kong, Mingrui Pang, Dingwen Zhang, Jiabin Yang, Jiancheng Chen, Yuanlong Li, Changhao Chen, Tianxin Lin
Journal: Cancer Research (2022)

Circular RNAs (circRNA) containing retained introns are normally sequestered in the nucleus. Dysregulation of cellular homeostasis can drive their nuclear export, which may be involved in cancer metastasis. However, the mechanism underlying circRNA nuclear export and its role in lymph node (LN) metastasis of bladder cancer remain unclear. Here, we identify an intron-retained circRNA, circNCOR1, that is significantly downregulated in LN metastatic bladder cancer and is negatively associated with poor prognosis of patients. Overexpression of circNCOR1 inhibited lymphangiogenesis and LN metastasis of bladder cancer in vitro and in vivo. Nuclear circNCOR1 epigenetically promoted SMAD7 transcription by increasing heterogeneous nuclear ribonucleoprotein L (hnRNPL)-induced H3K9 acetylation in the SMAD7 promoter, leading to inhibition of the TGFβ-SMAD signaling pathway. Nuclear retention of circNCOR1 was regulated by small ubiquitin-like modifier (SUMO)ylation of DDX39B, an essential regulatory factor responsible for circRNA nuclear-cytoplasmic transport. Reduced SUMO2 binding to DDX39B markedly increased circNCOR1 retention in the nucleus to suppress bladder cancer LN metastasis. By contrast, SUMOylated DDX39B activated nuclear export of circNCOR1, impairing the suppressive role of circNCOR1 on TGFβ-SMAD cascade activation and bladder cancer LN metastasis. In patient-derived xenograft (PDX) models, overexpression of circNCOR1 and inhibition of TGFβ signaling significantly repressed tumor growth and LN metastasis. This study highlights SUMOylation-induced nuclear export of circNCOR1 as a key event regulating TGFβ-SMAD signaling and bladder cancer lymphangiogenesis, thus supporting circNCOR1 as a novel therapeutic agent for patients with LN metastatic bladder cancer.This study identifies the novel intron-retained circNCOR1 and elucidates a SUMOylation-mediated DDX39B-circNCOR1-SMAD7 axis that regulates lymph node metastasis of bladder cancer.